Poly(ADP-ribose) polymerase activation in the reperfused myocardium

64Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

The activation of poly(ADP-ribose) polymerase (PARP) is now considered a final common effector in various types of tissue injury including systemic inflammation, circulatory shock and ischemia/reperfusion. Free radical and oxidant production and related cytotoxicity during ischemia/reperfusion leads to DNA strand breakage which activates the nuclear enzyme PARP and initiates an energy-consuming, inefficient cellular metabolic cycle with transfer of the ADP-ribosyl moiety of NAD+ to protein acceptors. During the last 5 years, a growing number of experimental studies demonstrated the beneficial effects of PARP inhibition in cell cultures through rodent models and more recently in pre-clinical large animal models of regional and global ischemia/reperfusion injury. The objective of the current review is to provide an overview of the experimental evidence implicating PARP as a pathophysiological modulator of myocardial injury in vitro and in vivo. © 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.

Cite

CITATION STYLE

APA

Szabó, G., Liaudet, L., Hagl, S., & Szabó, C. (2004, February 15). Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovascular Research. https://doi.org/10.1016/j.cardiores.2003.09.029

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free